| Literature DB >> 30377604 |
Jorge Henrique Assunção1, Guilherme Guelfi Noffs1, Eduardo Angeli Malavolta1, Mauro Emilio Conforto Gracitelli1, Ana Lucia Munhoz Lima1, Arnaldo Amado Ferreira Neto1.
Abstract
OBJECTIVE: To describe the clinical and epidemiological characteristics of patients with septic arthritis of the shoulder or elbow and to evaluate prognostic factors for complications during treatment.Entities:
Keywords: Elbow; Epidemiology; Infection; Septic arthritis; Shoulder
Year: 2018 PMID: 30377604 PMCID: PMC6204575 DOI: 10.1016/j.rboe.2017.08.025
Source DB: PubMed Journal: Rev Bras Ortop ISSN: 2255-4971
Fig. 1Sample distribution per age group.
Clinical and epidemiological characteristics of the sample.
| Shoulder | 17 (63%) |
| Elbow | 10 (37%) |
| Female | 15 (56%) |
| Male | 12 (44%) |
| 45.63 ± 22.60 | |
| Hematogenic | 21 (77%) |
| Contiguity | 5 (19%) |
| Direct inoculation | 1 (4%) |
| Community | 18 (67%) |
| Hospital | 9 (33%) |
| Fever | 19 (70%) |
| Pain | 27 (100%) |
| Leukocytosis | 15 (56%) |
| Elevated C-reactive protein and ESR | 27 (100%) |
| Gram staining | 12 (44%) |
| Positive synovial fluid culture | 24 (89%) |
| Interval for surgical treatment (days) | 11.56 ± 12.36 |
| 9 (33%) | |
| Systemic lupus erythematosus | 4 (14%) |
| Rheumatoid arthritis | 2 (7%) |
| Osteoarthrosis | 2 (7%) |
| Psoriatic arthritis | 1 (4%) |
| 18 (67%) | |
| Use of corticoids or immunosuppressants | 5 (18%) |
| Chronic kidney failure | 6 (22%) |
| Neoplasms | 2 (7%) |
| Acquired Immunodeficiency Syndrome | 2 (7%) |
| Hepatic cirrhosis | 2 (7%) |
| Sickle cell anemia | 1 (4%) |
| 23 (85%) | |
| Systemic hypertension | 9 (33%) |
| Diabetes | 4 (15%) |
| 14 (52%) | |
| Septic shock | 7 (26%) |
| Acute kidney failure | 4 (15%) |
| Hepatic failure | 2 (7%) |
| Acute myocardial infarction | 1 (4%) |
| Acute pancreatitis | 1 (4%) |
| Pulmonary complications | 3 (11%) |
| Death | 5 (19%) |
| 9 (33%) | |
| Chronic osteomyelitis | 4 (15%) |
| Osteochondral lesion | 2 (7%) |
| Rigidity | 4 (15%) |
| Surgical wound complications | 1 (4%) |
| Osteoarthrosis | 2 (7%) |
| 24 (89%) | |
| | 14 (52%) |
| | 2 (7%) |
| | 3 (11%) |
| | 2 (7%) |
| | 1 (4%) |
| | 1 (4%) |
| | 1 (4%) |
| 33 ± 22.28 | |
| Number of surgeries ≥2 | 8 (30%) |
| Change in empirical antibiotic therapy | 9 (33%) |
IQR, interquartile range; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus; ESR, erythrocyte sedimentation rate.
Mean.
Median.
Prognostic factors for orthopedic complications.
| Orthopedic complications | |||
|---|---|---|---|
| Yes | No | ||
| Shoulder | 5 (56%) | 12 (67%) | 0.683 |
| Elbow | 4 (44%) | 6 (33%) | |
| Female | 3 (33%) | 9 (50%) | 0.684 |
| Male | 6 (67%) | 9 (50%) | |
| 39 (IQR, 25–60) | 46.5 (IQR, 24.25–64.75) | 0.896 | |
| Hematogenic | 5 (56%) | 16 (89%) | 0.132 |
| Non-hematogenic | 4 (44%) | 2 (11%) | |
| Community | 5 (56%) | 13 (72%) | 0.667 |
| Hospital | 4 (44%) | 5 (28%) | |
| Fever | 7 (78%) | 12 (67%) | 0.657 |
| Pain | 9 (100%) | 18 (100%) | >0.999 |
| Leukocytosis | 3 (33%) | 12 (67%) | 0.217 |
| Elevated C-reactive protein and ESR | 9 (100%) | 18 (100%) | >0.999 |
| Gram staining | 3 (33%) | 9 (50%) | 0.683 |
| Positive synovial fluid culture | 8 (89%) | 16 (89%) | >0.999 |
| Interval for surgical treatment (days) | 17 (IQR, 10–20) | 5 (IQR, 3.25–7.5) | 0.0193 |
| 4 (44%) | 5 (28%) | 0.667 | |
| 7 (78%) | 11 (61%) | 0.667 | |
| 7 (78%) | 16 (89%) | 0.582 | |
| Systemic hypertension | 3 (33%) | 6 (33%) | >0.999 |
| Diabetes | 2 (22%) | 2 (11%) | 0.582 |
| Clinical complications | 5 (56%) | 9 (50%) | >0.999 |
| Other (includes methicillin-sensitive | 6 (75%) | 12 (75%) | >0.999 |
| Oxacillin-resistant | 2 (25%) | 4 (25%) | |
| 32 (IQR, 10–40) | 19.5 (IQR, 14.25–37.25) | 0.936 | |
| 5 (56%) | 3 (17%) | 0.072 | |
| 2 (22%) | 7 (39%) | 0.667 | |
IQR, interquartile range; ESR, erythrocyte sedimentation rate.
Prognostic factors for clinical complications.
| Clinical complications | |||
|---|---|---|---|
| Yes | No | ||
| Shoulder | 10 (71%) | 7 (54%) | 0.440 |
| Elbow | 4 (29%) | 6 (46%) | |
| Female | 7 (50%) | 5 (38%) | 0.704 |
| Male | 7 (50%) | 8 (62%) | |
| 43 (IQR, 24–59.5) | 46 (IQR, 25–61) | 0.719 | |
| Hematogenic | 11 (79%) | 10 (77%) | >0.999 |
| Non-hematogenic | 3 (21%) | 3 (23%) | |
| Community | 8 (79%) | 10 (85%) | 0.420 |
| Hospital | 6 (21%) | 3 (15%) | |
| Fever | 11 (79%) | 8 (62%) | 0.420 |
| Pain | 14 (100%) | 13 (100%) | >0.999 |
| Leukocytosis | 11 (79%) | 4 (31%) | 0.021 |
| Elevated CRP and ESR | 14 (100%) | 13 (100%) | >0.999 |
| Gram staining | 5 (36%) | 7 (54%) | 0.449 |
| Positive synovial fluid culture | 11 (79%) | 13 (100%) | 0.222 |
| Interval for surgical treatment (days) | 5.5 (IQR, 4–16.5) | 7 (IQR, 4–20) | 0.881 |
| 5 (36%) | 4 (30%) | >0.999 | |
| 10 (71%) | 8 (62%) | 0.695 | |
| 14 (100%) | 9 (69%) | 0.041 | |
| Systemic hypertension | 6 (43%) | 3 (23%) | 0.420 |
| Diabetes | 4 (29%) | 0 (0%) | 0.098 |
| 3 (21%) | 5 (38%) | 0.417 | |
| Other (includes methicillin-sensitive | 10 (71%) | 11 (85%) | 0.648 |
| Oxacillin-resistant | 4 (29%) | 2 (15%) | |
| 38 (IQR, 22.75–50.75) | 13 (IQR, 10–18) | 0.003 | |
| 4 (29%) | 4 (31%) | >0.999 | |
| 8 (57%) | 1 (8%) | 0.013 | |
IQR, interquartile range; ESR, erythrocyte sedimentation rate.